Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.

Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP, Goldstein DB.

Eur J Hum Genet. 2009 Jul;17(7):946-57. doi: 10.1038/ejhg.2008.264. Epub 2009 Jan 21.

2.

Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study.

Ramsey TL, Liu Q, Massey BW, Brennan MD.

Schizophr Res. 2013 Sep;149(1-3):21-5. doi: 10.1016/j.schres.2013.07.008. Epub 2013 Jul 23.

3.

The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.

Sacchetti E, Magri C, Minelli A, Valsecchi P, Traversa M, Calza S, Vita A, Gennarelli M.

Pharmacogenomics J. 2017 Mar;17(2):146-154. doi: 10.1038/tpj.2015.90. Epub 2016 Feb 9.

PMID:
26856250
4.

Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia.

Jenkins A, Apud JA, Zhang F, Decot H, Weinberger DR, Law AJ.

Neuropsychopharmacology. 2014 Aug;39(9):2170-8. doi: 10.1038/npp.2014.65. Epub 2014 Mar 14.

5.

A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia.

Gonçalves VF, Zai CC, Tiwari AK, Brandl EJ, Derkach A, Meltzer HY, Lieberman JA, Müller DJ, Sun L, Kennedy JL.

Neuropsychopharmacology. 2014 May;39(6):1347-54. doi: 10.1038/npp.2013.312. Epub 2013 Nov 7.

6.

Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.

Rajkumar AP, Poonkuzhali B, Kuruvilla A, Srivastava A, Jacob M, Jacob KS.

Psychopharmacology (Berl). 2012 Dec;224(3):441-9. doi: 10.1007/s00213-012-2773-2. Epub 2012 Jun 15.

PMID:
22700043
7.

Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.

Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL.

J Clin Psychiatry. 2001;62 Suppl 23:45-66. Review.

8.
9.

Pharmacogenetics of antipsychotics: recent progress and methodological issues.

Zhang JP, Malhotra AK.

Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):183-91. doi: 10.1517/17425255.2013.736964. Epub 2012 Dec 1. Review.

10.

Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study.

Liu Q, Jamba M, Patrick C 3rd, Padmanabhan S, Brennan MD.

Pharmacogenomics. 2012 Aug;13(11):1227-37. doi: 10.2217/pgs.12.105.

11.

The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

Naber D, Lambert M.

CNS Drugs. 2009 Aug;23(8):649-59. doi: 10.2165/00023210-200923080-00002.

PMID:
19594194
12.

The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain.

Zai GC, Zai CC, Chowdhury NI, Tiwari AK, Souza RP, Lieberman JA, Meltzer HY, Potkin SG, Müller DJ, Kennedy JL.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):96-101. doi: 10.1016/j.pnpbp.2012.05.014. Epub 2012 May 27.

PMID:
22642961
13.

Heterogeneity of treatment effects in schizophrenia.

Stroup TS.

Am J Med. 2007 Apr;120(4 Suppl 1):S26-31. Review.

PMID:
17403379
14.

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.

Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B.

Psychopharmacology (Berl). 2009 Oct;206(3):491-9. doi: 10.1007/s00213-009-1627-z. Epub 2009 Aug 13.

PMID:
19680635
15.

Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.

Campbell DB, Ebert PJ, Skelly T, Stroup TS, Lieberman J, Levitt P, Sullivan PF.

Biol Psychiatry. 2008 Jan 1;63(1):32-41. Epub 2007 Jun 22.

16.

Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Arranz MJ, Rivera M, Munro JC.

CNS Drugs. 2011 Nov 1;25(11):933-69. doi: 10.2165/11595380-000000000-00000. Review.

PMID:
22054119
17.

Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia.

Zhang JP, Lencz T, Geisler S, DeRosse P, Bromet EJ, Malhotra AK.

Schizophr Res. 2013 May;146(1-3):285-8. doi: 10.1016/j.schres.2013.01.020. Epub 2013 Feb 19.

18.

Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.

Houston JP, Kohler J, Bishop JR, Ellingrod VL, Ostbye KM, Zhao F, Conley RR, Poole Hoffmann V, Fijal BA.

J Clin Psychiatry. 2012 Aug;73(8):1077-86. doi: 10.4088/JCP.11m06916.

PMID:
22967772
19.

The CATIE schizophrenia trial: results, impact, controversy.

Manschreck TC, Boshes RA.

Harv Rev Psychiatry. 2007 Sep-Oct;15(5):245-58. Review.

PMID:
17924259
20.

Pharmacogenetics and schizophrenia.

Foster A, Miller DD, Buckley PF.

Psychiatr Clin North Am. 2007 Sep;30(3):417-35. Review.

PMID:
17720030

Supplemental Content

Support Center